Tesamorelin / CJC-1295 / Ipamorelin Blend
Also known as: Tesamorelin & CJC-1295 & Ipamorelin, Tesamorelin, CJC-1295 (No DAC), Ipamorelin
A potent three-part research blend pairing two GHRH analogs, Tesamorelin and CJC-1295 (No DAC), with the selective ghrelin agonist Ipamorelin. It is studied for strong synergistic GH release and visceral fat reduction.
Last updated
Mechanism of Action
Tesamorelin is a stabilized GHRH analog clinically shown to reduce visceral adipose tissue, while CJC-1295 (No DAC, modified GRF 1-29) is another GHRH-receptor agonist that amplifies GH pulse amplitude. Both act on the pituitary GHRH receptor, and Ipamorelin adds a complementary pulse through selective GHS-R1a (ghrelin) receptor activation with minimal cortisol or prolactin effect. The combination drives a strong synergistic increase in pulsatile GH and downstream IGF-1, with Tesamorelin contributing notable lipolytic and visceral-fat-reducing activity.
- Half-life
- Mixed: Tesamorelin ~26-38 minutes, CJC-1295 (No DAC) ~30 minutes, Ipamorelin ~2 hours
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Studied for strong synergistic GH release
- Investigated for visceral adipose tissue reduction
- Examined for improved body composition
- Researched for enhanced recovery and lean mass
- Studied for IGF-1 elevation via pituitary pathways
- Investigated for improved sleep quality
Potential Side Effects
- Injection-site redness, itching, or swelling
- Water retention and joint or muscle aches
- Tingling or numbness in extremities (carpal tunnel-like)
- Transient flushing or lightheadedness
- Possible reduction in insulin sensitivity at higher exposures
Common Dosing
Research-literature blends are studied at roughly 100-300 mcg of each component per administration, 1-2 times daily, often pre-sleep or fasted. For research-use only; not personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active malignancy or history of cancer
- Pregnancy or breastfeeding
- Known hypersensitivity to GHRH or ghrelin-receptor analogs
- Uncontrolled diabetes or significant glucose intolerance
Tesamorelin / Ipamorelin Blend
A research blend combining the visceral-fat-reducing GHRH analog Tesamorelin with the selective ghrelin agonist Ipamorelin. It is studied for synergistic GH release with a favorable metabolic profile.
CJC-1295 (No DAC) / Ipamorelin / GHRP-2 Blend
This three-peptide blend pairs CJC-1295 without DAC (a GHRH analog) with two ghrelin-mimetic secretagogues, Ipamorelin and GHRP-2, to maximize a clean, synergistic growth hormone pulse. All components are unapproved research peptides.
Fragment 176-191 / CJC-1295 / Ipamorelin Blend
A three-part research blend combining the lipolytic HGH Fragment 176-191 with the GHRH analog CJC-1295 (No DAC) and the selective ghrelin-receptor agonist Ipamorelin. It is studied for its combined effect on endogenous growth hormone release and fat metabolism.
- View
Ipamorelin, the first selective growth hormone secretagogue
1998
- View
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
2010
- View
Metabolic effects of a growth hormone-releasing factor in patients with HIV
2007
- View
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
2006